News

GSK to buy efimosfermin for up to $2 billion
GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating
Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...
GSK to Buy Liver Disease Drug For as Much as $2 Billion
GSK Plc agreed to buy an experimental medicine to treat liver diseases for as much as $2 billion as the UK drugmaker seeks to ...
GSK, partner iTeos scrap development of lung cancer therapy
Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...
BioSpace7h
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
FTSE 100 Live 14 May: GSK unveils $2bn acquisition, Imperial Brands posts results
Under the agreement to acquire Boston Pharmaceuticals' lead asset Efimosfermin, GSK will pay $1.2 billion upfront followed by ...
Explore more
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 ...
Fierce Biotech1d
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...